Efficacy of Ritlecitinib for Vitiligo Treatment Stratified by Baseline Demographic and Clinical Characteristics: Post Hoc Analysis of a Phase 2b Study

ABSTRACT Background Ritlecitinib demonstrated efficacy and safety in a phase 2b trial in patients with non‐segmental vitiligo (NSV). Objectives To explore the efficacy of ritlecitinib for the treatment of NSV in patient subgroups stratified by baseline demographic and clinical characteristics. Metho...

ver descrição completa

Detalhes bibliográficos

Principais autores:	A. G. Pandya, I. Hamzavi, P. Ghosh, K. Ezzedine, J. E. Harris, R. Adiri, S. Chen, E. Peeva, Y. Yamaguchi
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Wiley 2026-06-01
coleção:	JEADV Clinical Practice
Assuntos:	clinical research JAK3/TEC family kinase inhibitor nonsegmental vitiligo ritlecitinib vitiligo
Acesso em linha:	https://doi.org/10.1002/jvc2.70193
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!